DEXCOM, INC. vs ResMed Inc., two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where DXCM and RMD diverge most: on debt / equity, DXCM reads 0.47 and RMD reads 0.10; on p/b, DXCM reads 12.01 and RMD reads 4.74. The rest of the comparable metrics sit closer together. What RMD's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | DXCM | RMD |
|---|---|---|
| Price | $83.46 | $211.00 |
| Market cap | $31.5B | $30.7B |
| Sector | Medical Devices | Medical Devices |
| Stage | Growth | Mature |
| Implied growth (priced in) | — | +11.3% |
| P/E | 33.1 | 20.4 |
| P/B | 12.01 | 4.74 |
| P/S | 6.34 | 5.55 |
| EV/EBITDA | 22.5 | 14.1 |
| Revenue growth | +15.7% | +10.3% |
| Gross margin | 63.4% | 62.3% |
| Operating margin | 24.3% | 34.9% |
| Net margin | 20.1% | 27.4% |
| Return on equity | 38.1% | 23.4% |
| Return on assets | 15.5% | 17.3% |
| Return on invested capital | 23.1% | 21.0% |
| FCF yield | 4.5% | 5.7% |
| Dividend yield | — | 1.0% |
| Debt / equity | 0.47 | 0.10 |
| Current ratio | 1.73 | 3.01 |
| Altman Z (solvency) | 6.81 | 8.30 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.